Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × (225)Ac-PSMA-617 × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07054346 2026-04-01

LUTACT

University of California, San Francisco

Phase 1 Recruiting
45 enrolled
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡